Coherus Oncology Touts 90% Debt Cut, LOQTORZI Sales Surge, Sets 2026 Data Catalysts

Core Insights - Coherus is launching LOQTORZI for nasopharyngeal carcinoma (NPC), addressing an unmet medical need with an estimated 2,000 patients annually who previously relied on chemotherapy or off-label immuno-oncology treatments [1] - The company has undergone a significant transformation, enhancing its team, board, and investor base, and has recently completed a financing round, resulting in a strong balance sheet with cash reserves [2] - Coherus has reduced its debt by approximately 90%, from about $480 million to $3.7 million, and added $250 million to its balance sheet, which supports its oncology pipeline development [3][7] Commercial Launch and Financial Performance - LOQTORZI's commercialization is accelerating, generating about $19 million in sales in 2024, with sales doubling in 2025, and the company expects to reach a self-funding status at approximately $15-16 million per quarter by 2026 [6][8] - Management targets a run rate of roughly $175 million per year by 2028, representing about 70% penetration of a $250 million market opportunity [17] - LOQTORZI has shown a significant overall survival benefit of 65 months compared to 34 months with chemotherapy alone, and it is listed as the only "preferred" option in the NCCN guidelines for NPC [9] Pipeline Developments - Coherus is advancing its pipeline with tagmokitug (anti-CCR8) showing selective tumor Treg depletion of 52-97% without dose-limiting toxicities, and casdozokitug (anti-IL-27) demonstrating liver/lung-specific activity [5][16] - A randomized phase II readout for casdozokitug is expected in mid-2026, with ongoing studies showing improved response rates in liver cancer when combined with standard therapies [19][20] - The company is pursuing partnerships to share costs in pivotal trials for its pipeline assets, including collaborations with Johnson & Johnson [14][15] Strategic Focus - Coherus is focused on three main priorities: enhancing the commercial launch of LOQTORZI, advancing its pipeline assets, and implementing a financial strategy to reduce development costs while maximizing shareholder value [21]